RPS6KA1 and triple-negative breast carcinoma: Those patients could be offered a more intensive or adapted therapy and might represent potential candidates for a triple therapy with venetoclax/azacitidine and a RSK inhibitor, such as PMD-026 which is currently evaluated in a phase I clinical trial in triple negative breast cancer patients [49].